Team

OptMed has assembled a strong team to lead its efforts to successfully commercialize the product pipeline that it has under development.

Management team

CEO & DIRECTOR

Ervin Braun

As a serial entrepreneur for 30 years, Dr. Braun has been involved in the financial investment world through multiple venues, including investing in financial markets, angel investing, private equity, and real estate.

Learn More

He sits on the Board of Directors of OptMed and formerly of Gourmet Express, LLC, a frozen food company. He has also served as a consultant for several entertainment and social media companies, as well as advised on the development of Pencils of Promise, a highly visible and successful nonprofit organisation.

Dr. Braun has over 28 years of clinical experience and advanced training in Prosthodontics. He received his DMD from the University of Pennsylvania in 1978 and subsequently completed a fellowship in Maxillo-Facial Prosthetics in 1982 at Memorial Sloan-Kettering Hospital. In addition he possesses a Series 65 securities license and is a licensed insurance broker.

COO & FOUNDER

Alain Klapholz

Mr. Klapholz has served as a senior executive at a number of medical products companies over the past 26 years. He has built a strong track record in product and business development as well as finance at companies that include Ovabloc, Applied DNA Systems, and Ortec. Mr. Klapholz has led the development of multiple products that have received FDA approval and consults with medical device companies

CTO

Ciaran McArdle

Dr. Ciaran McArdle has over 35 years of R&D experience in industrial chemistry gained in large and entrepreneurial company settings. Most recently, he was a founding member of the start-up Afinitica Technologies S.L. that was acquired in 2018 by Arkema.

Learn More

He has held positions, with gradually increasing managerial responsibility in The General Electric Co. Ltd., Loctite Research, Development & Engineering Ltd., later acquired and integrated by Henkel AG & Co KGaA. Prior to his position of CTO in Afinitica from 2013 to 2020, Ciaran was Global Head of Advanced Technology in Henkel’s Adhesives Research Division managing a large international research group.

He has a PhD in Applied Polymer Chemistry and an MBA. Ciaran is considered to be an authority on all aspects of reactive monomer chemistry especially relating to product innovation. He has published over 30 papers and edited two monographs, and is lead inventor of more than 60 patents and now engages in several entrepreneurial activities.

Directors

CEO & DIRECTOR

Ervin Braun

As a serial entrepreneur for 30 years, Dr. Braun has been involved in the financial investment world through multiple venues, including investing in financial markets, angel investing, private equity, and real estate.

Learn More

He sits on the Board of Directors of OptMed and formerly of Gourmet Express, LLC, a frozen food company. He has also served as a consultant for several entertainment and social media companies, as well as advised on the development of Pencils of Promise, a highly visible and successful nonprofit organisation.

Dr. Braun has over 28 years of clinical experience and advanced training in Prosthodontics. He received his DMD from the University of Pennsylvania in 1978 and subsequently completed a fellowship in Maxillo-Facial Prosthetics in 1982 at Memorial Sloan-Kettering Hospital. In addition he possesses a Series 65 securities license and is a licensed insurance broker.

CO-CHAIRMAN

Marty Sands

CO-CHAIRMAN

Steven Sands

DIRECTOR

Richard Stone

has served as a member of our Board of Directors since July 2016. Professor Stone has taught at Columbia University Law School since 1974 and became Professor Emeritus in 2018. Professor Stone has taught courses in several fields of business law, specializing in federal income taxation.

Learn More

From 1969 to 1973, Professor Stone served in the United States Justice Department as Assistant to the Solicitor General of the United States. Beginning in 1981, Professor Stone began providing consulting to private and public technology start-ups, primarily in the biotechnology field. Professor Stone co-founded several biotechnology companies, including Lev Pharmaceuticals and Siga Technologies. In 2007, Professor Stone began working primarily with Israeli technology companies, mostly in the medical space. He is a member of the board of directors of Nano-X Imaging, Quality In Flow, LabStyle Innovations and Illumigyn. Professor Stone received his bachelor’s degree, Magna Cum Laude, from Harvard College, and his Juris Doctor degree, Magna Cum Laude, from Harvard Law School.

DIRECTOR

Ruiping Dong

Ruiping Dong is currently the Chairman Synecoun and the CEO at Haihe Biopharma.  Until the end of 2013, Ruiping was Senior Vice President and Head of Emerging Markets Research and Development, at Merck & Co.

Learn More

Dr. Ruiping DONG served as a member of the Research Laboratory Leadership (“RLT”) team, the Emerging Markets Leadership (“EMLT”) team and a Board of Director for Merck-Simcere Pharmaceutical joint venture.

Prior to Merck, Dr. Dong was the Vice President and Head of Research and Development for the Chinese and Japanese divisions at Bristol Myers-Squibb (“BMS”). In his role as Vice President of Global Medical Affairs, Emerging Markets and Asia-Pacific, Dr. Dong successfully built the research and development organization in China and Japan, defined the development strategy and aligned both the local and global functions.

Before BMS, Dr. Dong was a Medical Director for early oncology development at AstraZeneca U.S. and Department Head of Oncology and Pharmacology at AstraZeneca Japan. Dr. Dong led the early oncology development in the U.S. and successfully completed the launch of IRESSA in Japan, the first country to market the drug globally.

Dr. Dong earned his M.D. from Jiangxi Medical School in China, and his Ph.D. from Kyushu University Medical School in Japan. Before he joined the pharmaceutical industry, he worked as a research fellow at the Dana-Farber Cancer Institute at Harvard Medical School.

Medical Advisory Board

DOCTOR

Dr. Thomas Davenport

Dr. Thomas Davenport has been a partner at Long Island Plastic Surgical Group since 2006. He received his MD degree from Yale University. He completed both his residency in General Surgery and fellowship in Plastic Surgery in the Harvard University Program at the Massachusetts General Hospital.

Learn More

Dr. Davenport completed specialty training in Cancer Reconstruction and Cosmetic Surgery as a fellow at Memorial Sloan-Kettering Cancer Center. He completed his training in burn and accident reconstruction with Harvard University at the Shriner Burn Hospital for Children. Dr. Davenport specialises in treating complex wound problems, including wound care and burn reconstruction. Dr. Davenport is the division chief of plastic surgery and director of microsurgery at NYU Long Island Hospital. He has authored numerous articles and book chapters and lectured nationally and internationally on various aspects of plastic surgery and he is consultant for numerous companies.

DOCTOR

Dr. James Quinn

DOCTOR

Dr. Geoffrey Gurtner